Oxford Nanopore Technologies plc (LON:ONT)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.09B |
| Revenue (ttm) | 223.90M |
| Net Income (ttm) | -145.20M |
| Shares Out | 967.36M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 540,134 |
| Average Volume | 1,765,017 |
| Open | 114.90 |
| Previous Close | 114.90 |
| Day's Range | 111.00 - 114.90 |
| 52-Week Range | 104.00 - 224.80 |
| Beta | 0.88 |
| RSI | 44.50 |
| Earnings Date | Aug 19, 2026 |
About LON:ONT
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hardware, software, and chemistry. The company also provides PromethION 2 Solo, PromethION 2, PromethION 24, and PromethION 48. Its platform enables its cu... [Read more]
Financial Performance
In 2025, LON:ONT's revenue was 223.90 million, an increase of 22.22% compared to the previous year's 183.19 million. Losses were -145.20 million, -0.68% less than in 2024.
Financial StatementsNews
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
OXFORD, England & TOKYO--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations...
Oxford Nanopore Technologies Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue growth is strong in clinical and applied industrial markets, with rapid adoption in rare disease, infectious disease, and oncology. Technology differentiation, strategic partnerships, and biopharma applications are driving expansion, while financial targets have been adjusted to reflect market and execution challenges.
ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing
OXFORD, England & VIENNA--(BUSINESS WIRE)-- #Nanopore--ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's f...
Oxford Nanopore Technologies Earnings Call Transcript: H2 2025
Revenue grew 24% in FY 2025, with strong gains in clinical and applied markets, improved gross margins, and disciplined cost control. Guidance for FY 2026 targets 21%-25% revenue growth and 62% gross margin, with EBITDA breakeven expected in 2027.
Oxford Nanopore Technologies Transcript: Fireside Chat
Revenue and cash performance exceeded expectations, driven by strong growth in clinical and biopharma segments, a shift to a CapEx model, and ongoing innovation. Despite regional and execution challenges, the outlook remains positive with ambitious financial targets and new product launches expected to drive future growth.
Oxford Nanopore Technologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong revenue growth and market expansion were driven by differentiated sequencing technology, with clinical and biopharma segments showing rapid gains. Strategic innovation, new business models, and leadership transition position the company for continued growth and profitability.
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company's first IVD device registered in t...
Oxford Nanopore Technologies Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership transition is underway with a focus on biopharma and clinical growth, targeting EBITDA break-even by 2027. Technology differentiation and strong execution have driven top-end revenue guidance, with new pricing models and partnerships supporting margin and market expansion. Biopharma QC and clinical segments are key growth drivers.
Oxford Nanopore Technologies Transcript: Citi Annual Global Healthcare Conference 2025
Upgraded 2025 guidance reflects strong growth in the Americas and clinical/biopharma sectors, with major contracts like UK Biobank set to drive 2026 revenue. Pricing and business model changes have improved margins and cash flow, while operational focus shifts to high-value segments and leadership transitions support future scalability.
Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--At the American Society of Human Genetics (ASHG) 2025 industry session on 16th October, Oxford Nanopore Technologies will share its latest developments in...
Oxford Nanopore Technologies Earnings Call Transcript: H1 2025
Revenue grew 28% constant currency in H1 2025, with strong gains across all segments and regions. Gross margin reached 58.2% (61% excluding a one-off charge), and adjusted EBITDA loss improved 22% year-on-year. Guidance for 2025 is reaffirmed, with a focus on high-priority applied and clinical markets.
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)-- #Lifesciences--ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies (“Oxford Nanopore”) (L...
Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--A new paper, released this week on bioRxiv, introduces hifiasm-ONT, a breakthrough genome assembly algorithm that enables partially phased, near telomere-...
Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announced the expansion of its Compatible Products Programme (CPP), welcoming a new cohort of leading partners whose pr...
Oxford Nanopore Technologies Earnings Call Transcript: H2 2024
FY 2024 revenue grew 23% underlying to £183.2m, with strong H2 momentum and margin improvement. 2025 guidance is 20%-23% growth, factoring in US and China headwinds, with continued focus on applied, clinical, and biopharma markets and operational efficiency.
Oxford Nanopore Technologies Transcript: 43rd Annual J.P. Morgan Healthcare Conference
The platform achieved strong financial growth in 2024, driven by differentiated native DNA/RNA sequencing technology and expanding adoption in clinical, biopharma, and applied markets. Strategic innovation, new partnerships, and a robust pipeline support continued momentum and margin expansion into 2025 and beyond.
Oxford Nanopore Technologies Transcript: Piper Sandler 36th Annual Healthcare Conference
Nanopore technology enables high-accuracy, scalable sequencing across DNA, RNA, and future omics, with rapid clinical applications and strong positioning in population genomics. Strategic partnerships, innovation, and expanding global reach support growth, with financial targets set for margin improvement and break-even by 2028.
Oxford Nanopore and UK Biobank to create world's first epigenetic dataset targeting the causes of cancer, dementia, complex disease
OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a new collaboration with UK Biob...
Oxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK
OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a landmark strategic partnership with the UK ...
Oxford Nanopore Technologies Transcript: Bernstein Annual Pan-European Strategic Decisions Conference
Nanopore sequencing is driving a shift toward affordable, real-time, high-definition genomics, expanding from research into clinical, biopharma, and industrial markets. Strategic partnerships, global health initiatives, and a flexible business model support rapid growth, with financial targets set for over 30% annual revenue growth and profitability by 2027.
Oxford Nanopore Technologies Transcript: Bank of America Global Healthcare Conference 2024
Strong first-half growth and margin outperformance were driven by large contracts, increased device utilization, and improved sales force efficiency. New product launches and technology advances are expanding market opportunities, while operational discipline supports margin and revenue targets.
Oxford Nanopore Technologies Transcript: 21st Annual Goldman Sachs European Medtech and Healthcare Conference
Long-read sequencing technology is driving growth through unique capabilities in genomics, epigenomics, and applied markets, with strong H1 financials and robust guidance for the year. Expansion into biopharma, clinical, and population-scale programs, along with a scalable, cost-effective platform, positions the business for continued market share gains and margin improvement.
Oxford Nanopore Technologies Earnings Call Transcript: H1 2024
H1 2024 saw 12.4% revenue growth (constant currency) to £84.1m, with gross margin up to 58.8%. Full-year guidance of 20%-30% revenue growth and ~57% margin is reiterated, supported by strong cash reserves, new product launches, and major contract wins.
Oxford Nanopore Technologies and Plasmidsaurus Announce Strategic Collaboration to Advance Plasmid Sequencing
OXFORD, England, & LOS ANGELES--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies, the company behind a new generation of molecular sensing technology based on nanopores, and Plasmidsaurus, th...
Oxford Nanopore Technologies (ONT) - Product Pipeline Analysis 2024
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Oxford Nanopore Technologies Plc (ONT) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. Oxf...